Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Print: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v7.i3-4.70
pages 261-291

Oncogene-lnitiated Aberrant Signaling Engenders the Metastatic Phenotype: Synergistic Transcription Factor Interactions are Targets for Cancer Therapy

David T. Denhardt
Department of Cell, Developmental and Neurobiology and The Cancer Institute of New Jersey; Nelson Biological Laboratories, Rutgers University


Certain p21GTPases (notably Ras) and some of their guanine nucleotide exchange factors (e.g., Ost, Dbl, Tiam) and downstream mediators (e.g., Raf, Мус) have the potential to promote the development of malignancies because they can enhance the transcription of genes that foster the tumorigenic and metastatic phenotype. Among these are genes that stimulate cell proliferation, confer immortality, and facilitate the invasion of normal tissues. Oncogenes upstream of Ras—cell surface receptors such as ErbB2/Neu, Met, or Trk (and their ligands), and nonreceptor cytoplasmic protein tyrosine kinases such as Src and Abl—not only can act through Ras but also contribute additional signals. This review presents a synopsis of our understanding of signaling pathways controlled by the p21GTPases, with a focus on transcription factors regulated by the pathways. Mutations in one or more of the elements in these signaling pathways are invariably found in cancer cells. Crosstalk among the pathways may explain how some forms of stress can contribute to the development of a malignancy. Abnormal signaling leads to modified cytoskeletal structures and permanently altered (i.e., self-sustaining or epigenetic) transcription of target genes. A common theme is that genes whose transcription is elevated to the greatest extent by Ras often have in their promoters juxtaposed binding sites for two different transcription factors (particularly those in the Fos/Jun, CREB/ATF, NFκB, and Ets families) each of which is activated and such that together they synergize to augment transcription substantially. Some of these transcription factors can also act as oncogenes in certain cell types when appropriately modified and expressed. This unifying theme among many different cancers suggests that strategies to restore the balance among the signaling pathways or to suppress synergistic interactions between transcription factors may prove broadly useful in reversing the malignant phenotype.

Articles with similar content:

A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 5-6
Yuhao Wang, Benjamin Bonavida
Tumor Suppressor Maspin as a Rheostat in HDAC Regulation to Achieve the Fine-Tuning of Epithelial Homeostasis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 3
M. Margarida Bernardo, Shijie Sheng, Sijana Dzinic, Alexander Kaplun
Role of c-MET in Upper Aerodigestive Malignancies — From Biology to Novel Therapies
Journal of Environmental Pathology, Toxicology and Oncology, Vol.24, 2005, issue 3
Radha Uppalapati, Tanguy Y. Seiwert, Sascha Dietrich, Patrick C. Ma
Yin Yang 1 and raf-1 Kinase Inhibitory Protein Status in Hepatocellular carcinoma: Future Perspectives
Forum on Immunopathological Diseases and Therapeutics, Vol.1, 2010, issue 1-2
Luigi Inguglia, Melchiorre Cervello, Manuela Labbozzetta, Giuseppe Montalto, Rossana Porcasi, Lydia Giannitrapani, Paola Poma, Monica Notarbartolo, Natale D'Alessandro, Ada Maria Florena
Extracellular Vesicles as Potential Mediators of Epigenetic Reprogramming
Forum on Immunopathological Diseases and Therapeutics, Vol.6, 2015, issue 3-4
Anna Lewandowska Ronnegren